SCD and cancer: The mechanism by which SREBP-1 inhibition prevents cancer cell proliferation is through the reduction of SCD-1 expression and disruption of fatty acid desaturation, leading to lipotoxicity due to the abnormally high levels of saturated FAs [142,143,144].